Potential of IDH mutations as immunotherapeutic targets in gliomas: a review and meta-analysis.

Nazareno González Antonela Sofia AsadJosé Gómez EscalanteJorge A Peña AgudeloAlejandro Javier Nicola CandiaMatías García FallitAdriana Seilicovich Marianela Candolfi

Published in: Expert opinion on therapeutic targets (2022)

Data presented here indicates that the TIME not only differs in association with IDH mutation status, but also within glioma subtypes, suggesting that the cellular context affects the overall effect of this genetic lesion. Thus, specific therapeutic combinations may help patients diagnosed with different glioma subtypes.

Keyphrases

end stage renal disease
low grade
newly diagnosed
ejection fraction
high grade
prognostic factors
electronic health record
gene expression
patient reported outcomes
risk assessment
deep learning
patient reported
climate change